Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 2
2004 2
2005 3
2006 3
2007 5
2008 5
2009 3
2010 3
2011 3
2012 3
2013 1
2014 4
2015 5
2016 1
2017 3
2018 4
2019 4
2020 4
2021 1
2022 5
2023 5
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

63 results

Results by year

Filters applied: . Clear all
Page 1
Inhibition of CBP/β-catenin signaling ameliorated fibrosis in cholestatic liver disease.
Kimura M, Nishikawa K, Osawa Y, Imamura J, Yamaji K, Harada K, Yatsuhashi H, Murata K, Miura K, Tanaka A, Kanto T, Kohara M, Kamisawa T, Kimura K. Kimura M, et al. Among authors: kimura k. Hepatol Commun. 2022 Oct;6(10):2732-2747. doi: 10.1002/hep4.2043. Epub 2022 Jul 20. Hepatol Commun. 2022. PMID: 35855613 Free PMC article.
Feasibility, safety and tolerability of the CREB-binding protein/β-catenin inhibitor OP-724 in patients with advanced primary biliary cholangitis: an investigator-initiated, open-label, non-randomised, two-centre, phase 1 study.
Kimura M, Ogawa E, Harada K, Imamura J, Saio M, Ikura Y, Yatsuhashi H, Murata K, Miura K, Ieiri I, Tanaka A, Kimura K. Kimura M, et al. Among authors: kimura k. BMJ Open Gastroenterol. 2022 Nov;9(1):e001001. doi: 10.1136/bmjgast-2022-001001. BMJ Open Gastroenterol. 2022. PMID: 36442892 Free PMC article. Clinical Trial.
Molecular insights of a CBP/β-catenin-signaling inhibitor on nonalcoholic steatohepatitis-induced liver fibrosis and disorder.
Yamaji K, Iwabuchi S, Tokunaga Y, Hashimoto S, Yamane D, Toyama S, Kono R, Kitab B, Tsukiyama-Kohara K, Osawa Y, Hayashi Y, Hishima T, Tateno C, Kimura K, Okanoue T, Kohara M. Yamaji K, et al. Among authors: kimura k. Biomed Pharmacother. 2023 Oct;166:115379. doi: 10.1016/j.biopha.2023.115379. Epub 2023 Aug 28. Biomed Pharmacother. 2023. PMID: 37647690 Free article.
63 results